Ionis Pharmaceuticals, Inc.
IONS
$72.33
-$0.01-0.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 203.33M | 156.72M | 452.05M | 131.61M | 226.58M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 203.33M | 156.72M | 452.05M | 131.61M | 226.58M |
| Cost of Revenue | 287.60M | 220.09M | 221.61M | 202.22M | 249.32M |
| Gross Profit | -84.27M | -63.37M | 230.44M | -70.61M | -22.74M |
| SG&A Expenses | 130.19M | 96.81M | 90.62M | 76.25M | 88.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 417.79M | 316.90M | 312.23M | 278.47M | 337.40M |
| Operating Income | -214.46M | -160.18M | 139.82M | -146.86M | -110.82M |
| Income Before Tax | -227.92M | -128.39M | 123.53M | -146.82M | -107.04M |
| Income Tax Expenses | 1.48M | 213.00K | -20.00K | 116.00K | -2.69M |
| Earnings from Continuing Operations | -229.39M | -128.61M | 123.55M | -146.94M | -104.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -229.39M | -128.61M | 123.55M | -146.94M | -104.35M |
| EBIT | -214.46M | -160.18M | 139.82M | -146.86M | -110.82M |
| EBITDA | -210.56M | -157.31M | 142.68M | -144.05M | -108.12M |
| EPS Basic | -1.42 | -0.81 | 0.78 | -0.93 | -0.66 |
| Normalized Basic EPS | -0.88 | -0.62 | 0.56 | -0.57 | -0.41 |
| EPS Diluted | -1.42 | -0.81 | 0.70 | -0.93 | -0.66 |
| Normalized Diluted EPS | -0.88 | -0.62 | 0.49 | -0.57 | -0.41 |
| Average Basic Shares Outstanding | 162.00M | 159.77M | 159.14M | 158.74M | 158.00M |
| Average Diluted Shares Outstanding | 162.00M | 159.77M | 182.33M | 158.74M | 158.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |